1. Home
  2. TACHU vs GOVX Comparison

TACHU vs GOVX Comparison

Compare TACHU & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TACHU
  • GOVX
  • Stock Information
  • Founded
  • TACHU N/A
  • GOVX 2001
  • Country
  • TACHU
  • GOVX United States
  • Employees
  • TACHU N/A
  • GOVX N/A
  • Industry
  • TACHU
  • GOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TACHU
  • GOVX Health Care
  • Exchange
  • TACHU NYSE
  • GOVX Nasdaq
  • Market Cap
  • TACHU N/A
  • GOVX 15.5M
  • IPO Year
  • TACHU N/A
  • GOVX N/A
  • Fundamental
  • Price
  • TACHU $10.10
  • GOVX $1.02
  • Analyst Decision
  • TACHU
  • GOVX Strong Buy
  • Analyst Count
  • TACHU 0
  • GOVX 5
  • Target Price
  • TACHU N/A
  • GOVX $12.40
  • AVG Volume (30 Days)
  • TACHU N/A
  • GOVX 248.0K
  • Earning Date
  • TACHU N/A
  • GOVX 05-01-2025
  • Dividend Yield
  • TACHU N/A
  • GOVX N/A
  • EPS Growth
  • TACHU N/A
  • GOVX N/A
  • EPS
  • TACHU N/A
  • GOVX N/A
  • Revenue
  • TACHU N/A
  • GOVX $5,591,576.00
  • Revenue This Year
  • TACHU N/A
  • GOVX N/A
  • Revenue Next Year
  • TACHU N/A
  • GOVX N/A
  • P/E Ratio
  • TACHU N/A
  • GOVX N/A
  • Revenue Growth
  • TACHU N/A
  • GOVX N/A
  • 52 Week Low
  • TACHU N/A
  • GOVX $0.73
  • 52 Week High
  • TACHU N/A
  • GOVX $11.18
  • Technical
  • Relative Strength Index (RSI)
  • TACHU N/A
  • GOVX 50.40
  • Support Level
  • TACHU N/A
  • GOVX $0.93
  • Resistance Level
  • TACHU N/A
  • GOVX $1.16
  • Average True Range (ATR)
  • TACHU 0.00
  • GOVX 0.07
  • MACD
  • TACHU 0.00
  • GOVX 0.02
  • Stochastic Oscillator
  • TACHU 0.00
  • GOVX 54.84

About TACHU TITAN ACQUISITION CORP UNIT 1 COM CL A & 1/2 WT EXP 09/04/2030

Titan Acquisition Corp is a blank check company.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: